Publikationen

Grundlegende Voraussetzung für die flächendeckende Verbesserung der Behandlungskonzepte ist die Publikation der Forschungsergebnisse. iOMEDICO unterstützt die internationalen Richtlinien zu Transparenz und Veröffentlichung von medizinischen Forschungsergebnissen.

Wir präsentieren unsere Daten regelmäßig auf nationalen und internationalen Kongressen. Unsere Publikationen erscheinen in wissenschaftlich renommierten, internationalen Fachzeitschriften. Autoren sind die Studienleiter, Prüfärzte mit besonders hoher Patiententeilnahme und Wissenschaftler von iOMEDICO.

TITEL
STUDIE
JAHR
1st-line therapy of patients with Waldenström Macroglobulinemia: Treatment reality and outcome data from the German prospective TLN Registry.

Knauf, W., Slawik, H.R., Bückner, U., Houet, L., Wetzel, N., Jänicke, M., Marschner, N., 2018.

Oncol Res Treat 41 (suppl 4)(P181), 47-48

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLN
2018
MYRIAM: Prospective, intersectoral Real World cohort study for treatment and outcome of myeloma patients in Germany.

Knauf, W., Engelhardt, M., Lipke, J., Losem, C., Kasper, C., Dörfel, S., Houet, L., Vannier, C., Jänicke, M., Marschner, N., Dechow, T., Einsele, H., 2018.

Oncol Res Treat 41 (suppl 4)(P574), 190.

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
MYRIAM
2018
Survival of Non-Transplant Patients with Multiple Myeloma in Routine Care Differs from That in Clinical Trials—data from the Prospective German Tumour Registry Lymphatic Neoplasms.

Knauf, W., A. Aldaoud, U. Hutzschenreuter, M. Klausmann, S. Dille, N. Wetzel, M. Jänicke, N. Marschner, and the TLN-Group (Tumour Registry Lymphatic Neoplasms).

Annals of Hematology, 1 August 2018, 1–9. https://doi.org/10.1007/s00277-018-3449-8.

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: Annals of Hematology
TLN
2018
Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.

Fietz, T., Zahn, M.-O., Köhler, A., Engel, E., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., the TMK-Group (Tumour Registry Breast Cancer), 2018.

Breast Cancer Res Treat 167(2), 567–578. doi:10.1007/s10549-017-4534-8

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Breast Cancer Research and Treatment
TMK
2018
Results from the Prospective German TPK Clinical Cohort Study: Treatment Algorithms and Survival of 1,174 Patients with Locally Advanced, Inoperable or Metastatic Pancreatic Ductal Adenocarcinoma.

Hegewisch‐Becker, Susanna, Ali Aldaoud, Thomas Wolf, Beate Krammer‐Steiner, Hartmut Linde, Renate Scheiner‐Sparna, David Hamm, Martina Jänicke, and Norbert Marschner, 2018.

Epub ahead of print: International Journal of Cancer 0, no. ja. Accessed 19 July 2018. https://doi.org/10.1002/ijc.31751.

Abstract

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: - / Journal: International Journal of Cancer
TPK
2018
Final Effectiveness and Safety Results of NABUCCO – Real-World Data from a Non-Interventional, Prospective, Multi-Center Study in 697 Patients with Metastatic Breast Cancer Treated with Nab-Paclitaxel.

Marschner, N., C. Salat, U. Söling, R. Hansen, S. Grebhardt, J. Harde, A. Nusch, and K. Potthoff.

Epub ahead of print: Clinical Breast Cancer 0, no. 0 (15 July 2018). https://doi.org/10.1016/j.clbc.2018.07.010.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Clinical Breast Cancer
NABUCCO
2018
A brief instrument to measure health-related quality of life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-QoL-10).

Marschner, N., Wilke, J., Reschke, D., Kaiser, F., Schmoor, C., Grugel, R., Boller, E., 2018.

J Med Econ, 21(9), 920–929. doi:10.1080/13696998.2018.1484750

Abstract

Indikation: Other, Sonstige / Veranstaltung: - / Journal: Journal of Medical Economics
ARIE
2018
Effect of hypertension (HTN) on progression-free survival (PFS) in patients (pts) receiving front-line bevacizumab (BEV) for primary advanced ovarian cancer (OC) in the NOGGO single-arm OTILIA study: A post hoc analysis in 808 pts.

Armbrust, R., Wimberger, P., Mustea, A., Oskay-Özcelik, G., Keller, M., Richter, R., Harde, J., Zortel, M., Wegenaer, A., Tome, O., Sehouli, J., North-Eastern German Society of Gynaecological Oncology (NOGGO), 2018.

J Clin Oncol (Meeting Abstracts) 36 (suppl) abstr 5546.

Abstract

Indikation: Other, Ovarialkarzinom, Ovarian Cancer, Sonstige / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
OTILIA
2018
The Prospective Intersectoral National Cohort Study MYRIAM To Study Characteristics, Treatment And Outcome Of Patients With Multiple Myeloma In Germany.

Knauf, W., Engelhardt, M., Losem, C., Lipke, J., Kasper, C., Houet, L., Vannier, C., Jänicke, M., Marschner, N., Dechow, T., Einsele, H., 2018.

HemaSphere 2(S1)(PB2162), 967.

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: EHA / Journal: -
MYRIAM
2018
MANTA – A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.

Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., Makris, A., Nemsadze, G., Brunt, A.M., Kuemmel, S., Cabrero, I.R., Perelló, A., Kendall, A., Brown, J., Kristeleit, H., Conibear, J., Saura, C., Grenier, J., Máhr, K., Schenker, M., Sohn, J.H., Lee, K.S., Sarker, S.-J., Coetzee, C., Mousa, K., Castan, J.C., 2018.

Cancer Res 78(4 Supplement), GS2-07-GS2-07. doi:10.1158/1538-7445.SABCS17-GS2-07

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
MANTA
2018